Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Lidocaine and Prilocaine Cream USP, 2.5%/2.5% (USRLD: EMLA� Cream, 2.5%/2.5%). Lidocaine and Prilocaine Cream USP is indicated as a topical anaesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anaesthesia. Lidocaine and Prilocaine cream will be produced at the Group`s topical manufacturing site at Changodar, Ahmedabad. Lidocaine and Prilocaine cream had annual sales of USD 22.05 mn in the United States (IQVIA MAT October 2024). The group now has 412 approvals and has so far filed over 473* ANDAs since the commencement of the filing process in FY 2003-04. Powered by Capital Market - Live News

Zydus Lifesciences announced that Zydus Animal Health and Investments, a wholly owned subsidiary (ZAHL) had acquired 65,06,500 equity shares of Re. 1 each fully paid-up, representing 6.5% of the total paid-up share capital (Sale Shares) of Mylab Discovery Solutions (Mylab) from Rising Sun Holding (RHSPL) at an agreed consideration of Rs. 106 crore vide a Share Purchase Agreement (SPA) executed by ZAHL, RHSPL and Mylab on 23 June 2023. Now, pursuant to the terms and conditions of the SPA, ZAHL has exercised its Put Option right to sell the Sale Shares back to RHSPL and RHSPL has agreed to acquire the Sale Shares at the original consideration amount i.e. Rs. 106 crore. The Board of Directors of ZAHL at their meeting held today i.e. 16 December 2024, approved the disinvestment of Sale Shares, as per the terms and conditions of the SPA. Post that, ZAHL, RSHPL and Mylab have executed the termination deed. Powered by Capital Market - Live News

Net profit of Zydus Lifesciences rose 13.80% to Rs 911.20 crore in the quarter ended September 2024 as against Rs 800.70 crore during the previous quarter ended September 2023. Sales rose 20.08% to Rs 5113.60 crore in the quarter ended September 2024 as against Rs 4258.60 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales5113.604258.60 20 OPM %28.5826.91 - PBDT1504.501191.40 26 PBT1270.901007.20 26 NP911.20800.70 14 Powered by Capital Market - Live News

Zydus Lifesciences will hold a meeting of the Board of Directors of the Company on 12 November 2024Powered by Capital Market - Live News

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Fludrocortisone Acetate Tablets USP, 0.1 mg (USRLD: Florinef Tablets, 0.1 mg). Fludrocortisone acetate tablets are indicated as partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison`s disease and for the treatment of salt-losing adrenogenital syndrome. Fludrocortisone acetate tablets will be produced at the Group`s manufacturing site at Moraiya, Ahmedabad. Fludrocortisone acetate tablets had annual sales of USD 19.9 mn in the United States (IQVIA MAT July 2024).Powered by Capital Market - Live News